Pasithea Therapeutics (KTTA) Operating Leases (2022 - 2024)
Pasithea Therapeutics (KTTA) has disclosed Operating Leases for 3 consecutive years, with $32989.0 as the latest value for Q1 2024.
- Quarterly Operating Leases fell 92.91% to $32989.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $32989.0 through Mar 2024, down 92.91% year-over-year, with the annual reading at $81680.0 for FY2023, 76.26% down from the prior year.
- Operating Leases hit $32989.0 in Q1 2024 for Pasithea Therapeutics, down from $81680.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $724386.0 in Q3 2022 to a low of $32989.0 in Q1 2024.
- Historically, Operating Leases has averaged $331018.4 across 3 years, with a median of $351133.0 in 2022.
- Biggest five-year swings in Operating Leases: decreased 28.52% in 2023 and later tumbled 92.91% in 2024.
- Year by year, Operating Leases stood at $344021.0 in 2022, then crashed by 76.26% to $81680.0 in 2023, then crashed by 59.61% to $32989.0 in 2024.
- Business Quant data shows Operating Leases for KTTA at $32989.0 in Q1 2024, $81680.0 in Q4 2023, and $385288.0 in Q3 2023.